Hospital-Acquired Infection (HAI) Diagnostics Market: Global Overview & Forecast (2021-2030)

Market Snapshot

The global market for hospital-acquired infection (HAI) diagnostics was valued at approximately $3.4 billion in 2020 and is projected to nearly double, reaching around $7.0 billion by 2030. This growth represents a compound annual growth rate (CAGR) of 7.6% over the forecast period.

What Are Hospital-Acquired Infections?

Hospital-acquired infections - also referred to as nosocomial infections - are infections contracted by patients within a healthcare setting that are unrelated to their original reason for admission. These infections may originate from bacterial, viral, or fungal pathogens and can be transmitted through contact with infected patients, contaminated environments, or healthcare personnel. They pose a risk to all hospitalized individuals, with higher vulnerability observed among surgical patients, the elderly, and children.

Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/4447

Common types include:

Urinary tract infections (UTI)
Bloodstream infections
Surgical site infections
Hospital-acquired pneumonia
Gastrointestinal infections
Cardiovascular and bone/joint infections

HAIs are a global concern, contributing significantly to patient mortality across both developed and developing nations.

Market Drivers & Challenges

Growth drivers include:

Rising prevalence of hospital-acquired infections, particularly in developing economies with limited hygiene infrastructure
Growing public and institutional awareness about HAIs
Expansion and modernization of healthcare infrastructure
Increased investment in research and development
Technological advancements in diagnostic methods
Supportive government initiatives and policies

Key restraints include:

Low awareness of HAIs in low- and middle-income countries
Declining HAI rates in developed nations such as the U.S., Germany, and the UK, which can moderate demand growth

COVID-19 impact: The pandemic had a net positive effect on this market. As hospitalization rates surged globally and the risk of infection transmission within healthcare facilities intensified, demand for HAI diagnostic products rose considerably. The pandemic also accelerated adoption of point-of-care immunodiagnostic testing.

Market Segmentation

The HAI diagnostics market is segmented across several key dimensions:

By Product
Instruments and reagents/consumables form the two primary product categories. Reagents and consumables held the dominant share in 2020, generating revenues of approximately $2.09 billion, driven by persistent demand in low- and middle-income markets with high infection prevalence.

By Test Type
The market covers molecular diagnostics, immunoassay, and urinalysis. Immunoassay was the leading segment in 2020, accounting for roughly $1.63 billion in revenue, supported by rising incidences of infectious diseases, cancer, and pandemic-related demand.

By Application
The two primary application segments are disease testing and drug-resistance testing. Drug-resistance testing led in 2020 with revenues of about $2.67 billion, reflecting growing concern over antimicrobial resistance in clinical environments.

By Infection Type
Urinary tract infections were the top-performing infection category in 2020, contributing close to $950 million in revenue. This is consistent with UTIs being among the most commonly reported HAIs in hospitalized patients.

By End User
Hospitals represented the largest end-user segment in 2020, a trend largely reinforced by the sudden increase in patient volumes during the COVID-19 pandemic. Other end users include standalone laboratories and ambulatory surgery centers.

Enquire Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/4447

Regional Insights

North America was the largest regional market in 2020, generating approximately $1.55 billion in revenue. Factors driving this include a growing geriatric population and wide-scale adoption of advanced diagnostic technologies. Other key regions analyzed include Europe, Asia-Pacific, and LAMEA (Latin America, Middle East & Africa).

Competitive Landscape

The global HAI diagnostics market features several well-established players competing across product innovation, geographic reach, and technology capabilities. Leading companies include:

Abbott Laboratories, Bayer, Becton Dickinson & Company, Danaher Corporation, Ecolab, Hologic, Johnson & Johnson, Merck KGaA, Pfizer, and Steris PLC.

We offer customized report as per your requirement, please fill-up the form below.

https://www.alliedmarketresearch.com/request-for-customization/4447

Key Takeaways for Stakeholders

The market presents significant opportunities in emerging economies where HAI prevalence remains high and diagnostic infrastructure is still developing.

Point-of-care diagnostics and molecular testing are expected to see accelerated adoption going forward.

Drug-resistance testing is a critical growth area as antimicrobial resistance becomes a growing global health priority.

North America's established infrastructure and aging population make it a consistently strong revenue contributor, while Asia-Pacific offers strong long-term growth potential.

Media Contact:

Allied Market Research

United States: +1-503-894-6022

UK: +44-845-528-1300

India: +91 20 66346060

Email: help@alliedmarketresearch.com

Website: www.alliedmarketresearch.com

About Allied Market Research

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of market research reports, custom research solutions, and business intelligence. The company has an impressive portfolio of clients across industries, including technology, semiconductor & electronics, automotive, chemicals, food & beverage, energy & power, and healthcare.

This release was published on openPR.